Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed malignancy, including, but not limited to, any of the following:
• * Renal cell carcinoma
• * Melanoma
• * Kaposi's sarcoma
• * Breast, prostate, colorectal, or lung adenocarcinoma
• * Bone and soft tissue sarcomas
• * Lymphoma
• * Myeloma
• * Tumors of neuroendocrine and endothelial cell origin
• Stage IV disease
• Refractory disease, resistant to established treatments, or no effective treatment available
• Measurable or evaluable disease
• CNS metastases allowed if no prior definitive therapy within the past 3 months and no glucocorticoids required
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-1
• Granulocyte count \> 1,500/mm\^3
• Platelet count \> 100,000/mm\^3
• Creatinine \< 1.0 times upper limit of normal (ULN)
• Creatinine clearance ≥ 60 mL/min
• Bilirubin \< 1.5 times ULN
• AST/ALT \< 1.5 times ULN
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 3 months after completion of study treatment
• No history of any of the following:
• * Atrial fibrillation, atrial flutter, or other serious arrhythmia (excluding asymptomatic atrial and ventricular premature complexes)
• * Congestive heart failure currently requiring treatment
• * Angina pectoris
• * Other severe cardiovascular disease (i.e., New York Heart Association class III or IV heart disease)
• No baseline ECG abnormalities suggestive of cardiac conduction delay, i.e., 1° or greater atrio-ventricular block and/or complete or incomplete (QRS \> 120 ms) bundle branch block, or repolarization abnormalities (i.e., QTc ≥ 0.48 sec)
• No systemic infections requiring antibiotics within the past 14 days
• No known hepatitis B surface antigen positivity
• Psychologically prepared to participate in study treatment
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• At least 4 weeks since prior interferon (IFN) therapy and/or ≤ 400 million units of IFN
• At least 3 weeks since prior major surgery
• At least 3 weeks since prior radiation therapy or chemotherapy
• No prior solid organ allografts or allogeneic bone marrow transplantation
• No concurrent daily glucocorticoids except for physiological replacement
• No other concurrent medications known to prolong QT interval